Evaluating the impact of bevacizumab maintenance therapy on overall survival in advanced non-small-cell lung cancer

Clinical Lung Cancer

Volumn 14, Issue 2, 2013, Pages 120-127

  Dranitsaris, George ^a,d   Beegle, Nancy ^a   Ravelo, Arliene ^b   Kalberer, Traci ^a   Yu, Elaine ^b   Thomas, Sachdev ^c  

^a Cancer Clinics of Excellence   (United States)

^b GENENTECH INC   (United States)

^c Illinois Cancer Care   (United States)

^d Cancer Clinics of Excellence   (Canada)

Author keywords

Bevacizumab; Effectiveness; Maintenance therapy; Non small cell lung cancer; Safety

Indexed keywords

BEVACIZUMAB;

ADULT; ADVANCED CANCER; AGE DISTRIBUTION; AGED; ARTICLE; BLEEDING; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER PROGNOSIS; CANCER SURVIVAL; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HYPERTENSION; LUNG NON SMALL CELL CANCER; MAINTENANCE CHEMOTHERAPY; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OVERALL SURVIVAL; RETROSPECTIVE STUDY; RISK REDUCTION; TREATMENT RESPONSE; UNITED STATES; VENOUS THROMBOEMBOLISM;

AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 84875245145     PISSN: 15257304     EISSN: 19380690     Source Type: Journal    
DOI: 10.1016/j.cllc.2012.06.002     Document Type: Article

References (25)

1. P. Marino, S. Pampallona, A. Preatoni Chemotherapy vs. supportive care in advanced non-small-cell lung cancer: results of a meta-analysis of the literature Chest 106 1994 861 865
2. Chemotherapy in non-small cell lung cancer: a meta-analysis using up-dated data on individual patients from 52 randomized clinical trials. Non-small Cell Lung Cancer Collaborative Group BMJ 311 1995 899 909
3. L. Jaakkimainen, P.J. Goodwin, J. Pater Counting the costs of chemotherapy in a National Cancer Institute of Canada randomized trial in nonsmall cell lung cancer J Clin Oncol 8 1990 1301 1309
4. M.D. Vincent Optimizing the management of advanced non small cell lung cancer: a personal view Curr Oncol 16 2009 219 231
5. W.C. Dempke, T. Suto, M. Reck Targeted therapies for non-small cell lung cancer Lung Cancer 67 2010 257 274
6. T. Ciuleanu, T. Brodowicz, C. Zielinski Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for nonsmall cell lung cancer: a randomised, double blind phase 3 study Lancet 374 2009 1432 1440
7. F. Cappuzzo, T. Ciuleanu, L. Stelmakh Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study Lancet Oncol 11 2010 521 529
8. E. Felip, C. Gridelli, P. Baas Metastatic non-small-cell lung cancer: consensus on pathology and molecular tests, first-line, second-line, and third-line therapy: 1st ESMO Consensus Conference in lung cancer; Lugano 2010 Ann Oncol 22 2011 1507 1519
9. A. Sandler, R. Gray, M.C. Perry Paclitaxel-carboplatin alone or with bevacizumab for non small cell lung cancer N Engl J Med 355 2006 2542 2550
10. M. Reck, J. von Pawel, P. Zatloukal Phase III trial cisplatin plus germcitabine with either placebo or bevacizumab as first-line therapy for non squamous non-small-cell lung cancer: AVAIL J Clin Oncol 27 2009 1227 1234
11. T.K. Owonikoko, S.S. Ramalingam, C.P. Belani Maintenance therapy for advanced non-small cell lung cancer: current status, controversies, and emerging consensus Clin Cancer Res 16 2010 2496 2504
12. J. Tabernero The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents Mol Cancer Res 5 2007 203 220
13. R.G. Zinner, S.B. Saxman, G. Peng Treatment rationale and study design for a randomized trial of pemetrexed/carboplatin followed by maintenance pemetrexed versus paclitaxel/carboplatin/bevacizumab followed by maintenance bevacizumab in patients with advanced non-small-cell lung cancer of nonsquamous histology Clin Lung Cancer 11 2010 352 357
14. J. Carroll Payers step in with 'real-world' comparative effectiveness research Manag Care 20 2011 23 26
15. S.M. Teutsch, J.E. Fielding Comparative effectiveness: looking under the lamppost JAMA 305 2011 2225 2226
16. T. Byers, R.L. Sedjo Does intentional weight loss reduce cancer risk? Diabetes Obes Metab 13 2011 1063 1072
17. K. Cooper, H. Squires, C. Carroll Chemoprevention of colorectal cancer: systematic review and economic evaluation Health Technol Assess 14 2010 1 206
18. S. Guo, M.W. Fraser Propensity Score Analysis: Statistical Methods and Applications 2011 Sage University Press Thousand Oaks (CA)
19. J.R. Anderson, K.C. Cain, R.D. Gelber Analysis of survival by tumor response J Clin Oncol 1 1983 710 719
20. J.R. Anderson, K.C. Cain, R.D. Gelber Analysis of survival by tumor response and other comparisons of time-to-event by outcome variables J Clin Oncol 26 2008 3913 3915
21. P.R. Rosenbaum, D.B. Rubin The central role of the propensity score in observational studies for causal effects Biometrika 70 1983 41 55
22. S. Weitzen, K.L. Lapane, A.Y. Toledano Principles for modeling propensity scores in medical research: a systematic literature review Pharmacoepidemiol Drug Saf 13 2004 841 853
23. R.L. Fleurence, H. Naci, J.P. Jansen The critical role of observational evidence in comparative effectiveness research Health Aff (Millwood) 29 2010 101826 101833
24. M.H. Cohen, J.R. Johnson, S. Chattopadhyay Approval summary: erlotinib maintenance therapy of advanced/metastatic non-small cell lung cancer (NSCLC) Oncologist 15 2010 1344 1351
25. E. Nadler, E. Yu, A. Ravelo Bevacizumab treatment to progression after chemotherapy: outcomes from a U.S. community practice network Oncologist 16 2011 486 496